Substrate partitioning & insulin control
One of 6 mechanistic pathways to 🔥 Lose fat · 17 options
Where a calorie goes matters as much as how many arrive. Chronically elevated insulin keeps hormone-sensitive lipase switched off — you cannot mobilize fat you are simultaneously storing. Improve glucose disposal and you change the destination of the same food.
This is the pathway with the clearest test. Fasting insulin above roughly 8 µIU/mL, triglyceride:HDL above 2, or raised uric acid all point at insulin resistance — and if that's your picture, this pathway outranks every other one on the page for you specifically.
Fasting InsulinHbA1c (Hemoglobin A1c)Lipid Panel (Cholesterol, HDL, LDL, Triglycerides)Uric AcidComprehensive Metabolic Panel (CMP)📉 Insulin Resistance Deep Dive covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
🧬 White Kidney Bean Extract
A characterized alpha-amylase inhibitor — the protein is real and the enzyme block is measurable in a tube. What it buys in a person is smaller than the mechanism implies: the balance studies recover far less stool energy than a full block predicts, because inhibiting amylase mostly moves starch digestion further down the gut rather than preventing it. Dose is expressed in amylase-inhibiting units, and the shelf product rarely matches the standardized extract the trials used.
🧬 Chitosan
A cationic polysaccharide that binds fatty acids and bile acids electrostatically — 77% binding capacity in a beaker, and about a gram a day of extra fecal fat in a person. The honest comparison is orlistat, a real lipase inhibitor, whose number is several times larger. Degree of deacetylation and molecular weight both decide the binding and neither is on the label.
🧬 PGX
The one in this group whose claim is physically measurable: a konjac/alginate/xanthan blend that raises the viscosity of gut contents and slows glucose appearance. It claims a delay rather than a blockade, and the acute glycemic data are correspondingly good. The open question is whether the proprietary blend beats plain glucomannan, which costs a fraction and works by the same physics.
💉 Metformin
Complex-I inhibition raises the AMP:ATP ratio and activates AMPK; hepatic glucose output falls. Weight effect is modest and real. The most studied molecule on this entire page.
💉 Acarbose
Blocks α-glucosidase so complex carbohydrate is digested more slowly and further down the gut. Flattens the glucose curve and feeds the colonic microbiome — which is likely why it extends lifespan in mice.
💉 Canagliflozin
SGLT2 inhibition dumps roughly 200–300 kcal of glucose into the urine daily. Weight loss is real and mostly a direct calorie-excretion effect, with a genital-mycotic-infection cost.
💉 Amlexanox
Inhibits TBK1 and IKKε, two kinases that keep obese adipose tissue in a low-grade inflammatory, energy-conserving state. In mice it reverses insulin resistance and drives weight loss; a small human trial showed glucose improvement in responders only.
💉 GC-1
A thyroid-hormone-β-receptor-selective agonist (sobetirome). The design intent is hepatic lipid clearance and raised metabolic rate without the cardiac β1 effects of T3. Elegant mechanism, essentially no human fat-loss data.
💉 MK-677
Raises GH and IGF-1 around the clock. Increases lean mass reliably — but also appetite and fasting glucose, which makes it an actively poor fat-loss tool despite the body-composition marketing.
🧬 Myo-Inositol
Acts as a second messenger downstream of the insulin receptor. Strong trial support for insulin sensitivity in PCOS specifically, which is where the fat-loss extrapolation is best founded.
🧬 Chromium
Cofactor for insulin signaling. Supplementation helps meaningfully only where intake was low; the general fat-loss claim has not survived meta-analysis.
🧬 Ceylon Cinnamon
Improves fasting glucose modestly in trials. True Ceylon rather than cassia matters because cassia's coumarin load is hepatotoxic at habitual doses.
🧬 Apple Cider Vinegar
Acetic acid slows gastric emptying and blunts the post-prandial glucose spike. Small, replicated, and cheap.
🧬 Gymnema Sylvestre
Beyond taste-receptor blockade, gymnemic acids may reduce intestinal glucose absorption. Second mechanism, weaker evidence.
🧬 Magnesium
Cofactor for over 300 enzymes including several in the insulin-signaling cascade. Correcting a deficit improves insulin sensitivity measurably — this is repletion, not pharmacology.
🧬 Metabolic Health
A formulated blend aimed at the same pathway. Judge it on its components, not its name.
🧬 Taurine
Depleted by beta-agonists and involved in bile-acid conjugation and glucose handling. Supportive rather than driving.
What actually decides this outcome, in order of size
Insulin is a storage signal, and while it is elevated, hormone-sensitive lipase is suppressed. Every product here is trying to change where a given amount of substrate ends up. Ranked by how much of the outcome each factor owns:
- Insulin sensitivity, which is set mostly by muscle mass, activity and sleep. Skeletal muscle is the largest site of insulin-mediated glucose disposal, and contraction moves glucose into it through a route that does not require insulin at all. That is the largest lever on this page and none of it is purchasable.
- WHERE THE ENERGY GOES WHEN A DRUG REMOVES IT, WHICH IS THE DIRECTION QUESTION AND HAS A DIFFERENT ANSWER FOR EACH AGENT. Acarbose does not remove carbohydrate; it delays digestion so more reaches the colon, which is why its dose-limiting effect is gastrointestinal and also why it has been argued to promote metabolic health through fermentation DiNicolantonio 2015. An SGLT2 inhibitor removes glucose in urine, and the program-level outcome data covers both the benefits and the harms Chen 2024 Sharma 2024. Partitioning relocates; it does not delete.
- What metformin actually does, which has been revised. The mechanisms of action and repurposing potential have been updated Foretz 2023, complex IV inhibition has been examined alongside phenformin and galegine LaMoia 2022, and the long-term effects and effect heterogeneity in the Diabetes Prevention Program outcomes study have been reported Knowler 2025. Heterogeneity is the operative word: the average effect is not the individual one.
- What the drug costs in a nutrient, which is the most under-monitored item here. The impact of metformin on cobalamin status in people with type 2 diabetes has been assessed Fituri 2023. That is a measurable, correctable, frequently ignored consequence of a drug people take for years.
- Whether the postprandial curve or the average is the target. Acarbose has been assessed for cardiovascular risk factors in impaired glucose regulation Zamani 2023 and compared with sitagliptin for glucose fluctuation alongside metformin Cai 2025. A flat average can hide a spiking curve, which is the argument developed at Glucose disposal, absorption & the post-meal curve.
- Whether the botanical has a trial or a mechanism. Inositol has a systematic review and meta-analysis in polycystic ovary syndrome Fitz 2024 Greff 2023; gymnema has a glycemic control trial Gaytan Martinez 2021; vinegar's antiglycemic properties have been examined in healthy adults Johnston 2010 and over eight weeks on glucose homeostasis Jasbi 2019. Those are real and small, and they are not in the same units as the prescription arm.
The order to run these in, and what has to be true first
Measure first, because the numbers decide which half of this page applies and whether any of it does. Then treat the mechanism the numbers point at rather than the one the marketing does.
- Baseline bloods, which are the whole basis for choosing anything. Fasting Insulin with HbA1c (Hemoglobin A1c), a Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), a Comprehensive Metabolic Panel (CMP), Uric Acid and Vitamin B12. A C-Peptide, Serum if the picture is unclear. Fasting insulin is the number this page is named after and the one least often ordered.
- Resistance training and sleep before pharmacology. Muscle is the disposal site and contraction-mediated uptake is insulin-independent, which is why this outranks the shelf and why it is listed as a step rather than as encouragement.
- Myo-Inositol is the best-evidenced supplement here and its evidence is in a specific population. The systematic reviews are in polycystic ovary syndrome Fitz 2024 Greff 2023, which is where it belongs — see PCOS — insulin, androgens & ovulation.
- Magnesium, Chromium and Taurine are cofactor-level interventions. Correcting a measured deficiency is a different act from supplementing a replete adult, and only the first has a plausible effect size.
- Apple Cider Vinegar, Ceylon Cinnamon and Gymnema Sylvestre are the food-level arm with real but small trials Johnston 2010 Jasbi 2019 Gaytan Martinez 2021. Ceylon rather than cassia matters because of coumarin content, which is a hepatic safety point rather than an efficacy one.
- Metformin is the prescription with the deepest literature and the most revision Foretz 2023 LaMoia 2022. The long-term prevention data reports effect heterogeneity Knowler 2025, and the cobalamin consequence is measurable and should be measured Fituri 2023.
- Acarbose acts in the gut lumen and its effects follow from that DiNicolantonio 2015 Zamani 2023 Cai 2025. The gastrointestinal effects are the mechanism rather than a side effect.
- Canagliflozin is a urinary glucose route and its outcome data includes both directions Chen 2024 Sharma 2024. Amlexanox is an inhibitor of inflammatory kinases with a mechanistic rationale in catecholamine resistance Mowers 2013; GC-1 is a thyroid receptor agonist and belongs at Thyroid & thermogenic substrate; MK-677 raises growth hormone and worsens insulin sensitivity, which is the opposite direction to this page and is covered at GH / IGF-1 axis. Metabolic Health is a fixed blend whose doses somebody else chose.
What gets bought for this that cannot move it
The category that fails structurally is the glucose-disposal supplement bought as a partitioning agent. Cinnamon, chromium and gymnema act on absorption or on modest insulin signaling changes Gaytan Martinez 2021 Johnston 2010 Jasbi 2019, and their effect sizes are food-level. They are being sold on the same page as drugs with outcome trials Chen 2024 Knowler 2025, which invites a reader to substitute one for the other and conclude the mechanism does not work. The mechanism works. The doses are not comparable.
The direction failure is that partitioning moves a destination and each destination has a price. Acarbose delays carbohydrate digestion so more reaches the colon, which is why the gastrointestinal effects are inseparable from the mechanism DiNicolantonio 2015. SGLT2 inhibition removes glucose in urine, and the program-level data reports the harms alongside the benefits Chen 2024 Sharma 2024 — genital infection and euglycemic ketoacidosis being the ones a reader should recognize. There is no route that removes energy without a consequence somewhere, and a page listing only the benefit half has described half a mechanism.
The cost that goes unmeasured for years. Metformin's effect on cobalamin status is documented and testable Fituri 2023, and the presentation of a deficiency — fatigue, altered sensation — is easily attributed to something else. Effect heterogeneity in the long-term prevention data Knowler 2025 is the other side of the same point: average benefit does not tell an individual what their own result was.
The reader this page is the wrong page for. If food is a source of distress rather than a quantity problem, if eating is already restricted, or if the relationship with eating is what actually needs attention, then a page about insulin pharmacology is the wrong instrument and the right step is a clinician who works with eating rather than a drug that changes where substrate goes. That is not a hedge; it is the honest boundary of what this page covers.
If the goal underneath is different, so is the page. If the target is the post-meal curve specifically, Glucose disposal, absorption & the post-meal curve. If it is fuel sensing, AMPK activation & cellular fuel sensing. If it is liver fat, Hepatic fat & fatty liver. If it is the incretin system, Incretin & satiety signaling. And polycystic ovary syndrome as the underlying diagnosis is PCOS — insulin, androgens & ovulation.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. Fasting Insulin will move before HbA1c (Hemoglobin A1c) does on anything that genuinely changes insulin sensitivity, which makes it the earlier and more informative of the two; and no supplement on this page will change either number by an amount that would be visible against ordinary week-to-week variation.
- Fasting Insulin with HbA1c (Hemoglobin A1c) at baseline and 12 weeks. Twelve weeks because glycated hemoglobin integrates over roughly the life of a red cell, while fasting insulin responds within weeks — the gap between them is the useful signal.
- Vitamin B12 at baseline and annually on Metformin. The consequence is documented Fituri 2023, the correction is trivial, and the deficiency is routinely attributed to something else for years.
- A Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) with a Comprehensive Metabolic Panel (CMP) at baseline and 12 weeks. Triglycerides track insulin resistance closely enough to be a useful second read-out, and liver chemistry catches the fatty-liver overlap that sends readers to a different page.
- Uric Acid at baseline and 12 weeks. It tracks with insulin resistance, it is on every basic panel, and it costs nothing extra.
- Urinalysis, Routine and a C-Peptide, Serum where the agent or the picture calls for it. Urinalysis because glucose in urine is the mechanism of one drug class rather than an abnormality Chen 2024; C-peptide when it is unclear whether the problem is insulin resistance or insufficient secretion, because that distinction changes everything on this page.
What will fool you. A single fasting insulin has meaningful day-to-day variation, so a change of a few units between two draws is noise rather than a response. Anything that changes what was eaten the day before a draw changes the draw. Glucose appearing in urine on an SGLT2 inhibitor is the drug working, not a new diagnosis Chen 2024. Gastrointestinal effects on Acarbose are the mechanism rather than intolerance DiNicolantonio 2015. And a supplement trialed across a period when training or sleep also changed has been credited with someone else's work — which is why one change at a time is the only design that answers anything here.
Sources read for these sections
- Zamani M, et al. The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose-response meta-analysis. Frontiers in Nutrition 2023 · PMID 37599681
- DiNicolantonio JJ, et al. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart 2015 · PMID 26512331
- Cai X, et al. Comparison of glucose fluctuation between metformin combined with acarbose or sitagliptin in Chinese patients with type 2 diabetes. Chinese Medical Journal 2025 · PMID 40178116
- Foretz M, et al. Metformin: update on mechanisms of action and repurposing potential. Nature Reviews Endocrinology 2023 · PMID 37130947
- LaMoia TE, et al. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. Proceedings of the National Academy of Sciences 2022 · PMID 35238637
- Knowler WC, et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes and Endocrinology 2025 · PMID 40311647
- Fituri S, et al. Impact of metformin treatment on cobalamin status in persons with type 2 diabetes. Nutrition Reviews 2023 · PMID 37167532
- Chen AX, et al. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2024 · PMID 39036974
- Sharma A, et al. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 2024 · PMID 38240199
- Fitz V, et al. Inositol for Polycystic Ovary Syndrome: a systematic review and meta-analysis to inform the 2023 update of the International Evidence-Based PCOS Guidelines. Journal of Clinical Endocrinology and Metabolism 2024 · PMID 38163998
- Greff D, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology 2023 · PMID 36703143
- Gaytan Martinez LA, et al. Effect of Gymnema sylvestre Administration on Glycemic Control, Insulin Secretion, and Insulin Sensitivity in Patients with Impaired Glucose Tolerance. Journal of Medicinal Food 2021 · PMID 32460589
- Johnston CS. Examination of the antiglycemic properties of vinegar in healthy adults. Ann Nutr Metab 2010 · PMID 20068289
- Jasbi P. Daily red wine vinegar ingestion for eight weeks improves glucose homeostasis and affects the metabolome but does not reduce adiposity in adults. Food Funct 2019 · PMID 31647087
- Mowers J, et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKepsilon and TBK1. eLife 2013 · PMID 24368730
The other 5 routes to lose fat
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Lose fat Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Lose fat Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
Where a calorie goes matters as much as how many arrive. Chronically elevated insulin keeps hormone-sensitive lipase switched off — you cannot mobilize fat you are simultaneously storing. Improve glucose disposal and you change the destination of the same food.
17 options are mapped to this pathway in the Vault, including White Kidney Bean Extract, Chitosan, PGX, Metformin. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 7 carry clinical validation and 8 are mechanistic predictions.
This is the pathway with the clearest test. Fasting insulin above roughly 8 µIU/mL, triglyceride:HDL above 2, or raised uric acid all point at insulin resistance — and if that's your picture, this pathway outranks every other one on the page for you specifically. The markers worth checking are Fasting Insulin, HbA1c (Hemoglobin A1c), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), Uric Acid.
Unproven is not the same as ineffective. Of the 17 options on this pathway, 7 have clinical validation and 8 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Substrate partitioning & insulin control. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.